Rat climbing behavior elicited by stimulation of cerebral dopamine receptors
- 1 January 1984
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie
- Vol. 325 (2) , 93-101
- https://doi.org/10.1007/bf00506188
Abstract
The experimental conditions allowing to elicit by administration of dopamine agonists a climbing behavior in rats, apparently analogous to the stereotyped cage climbing behavior previously described in mice (Protais et al. 1976), have been established. Among the various strains of rats studied i.e. Sprague-Dawley, Long Evans and Wistar, the latters were selected as the most responsive to the dopamine agonist apomorphine. However, even in the Wistar strain, only about 60% of animals responded to a test-dose of 0.4 mg/kg apomorphine by adopting in a sustained manner the typical upright position against the walls of a suitable experimental cage. Hence responsive rats were preselected 4 days before the experimental sessions and finally rated during a 60-min observation period. Increasing the test-dose of apomorphine led to a biphasic effect, the spontaneous climbing behavior being decreased at low dosage and, then, both the percentage of climbing animals and the duration of the behavior were progressively increased at higher dosages. A scoring system based on an all-or-none evaluation of the frequency of stereotyped climbing episods over the 1 h observation period was finally adopted allowing to establish dose response curves to apomorphine and its more potent derivative N-propylnorapomorphine. Dexamphetamine (associated to L-Dopa) also produced the stereotyped climbing behavior. The latter was completely abolished in animals treated with the “atypical” antipsychotic sulpiride. The effects of lesioning various cerebral dopaminergic areas on the apomorphine-induced behavior were investigated. The response was not significantly altered following bilateral thermocoagulations of the striatum (restricted lesions), globus pallidus, nucleus interstitialis of the striae terminalis, amygdala, nucleus lateralis septi or nucleus accumbens. Intrastriatal injections of 6-hydroxydopamine were without significant effect while large striatal thermocoagulations abolished the stereotyped behavior but were accompanied by a profound motor deficiency. Bilateral lesioning of the substantia nigra by either thermocoagulation or 6-hydroxydopamine, the latter leading to a 60% decrease in 3H-dopamine uptake in striatum without significant modification in nucleus accumbens, resulted in a hypersensitive response to apomorphine. Hence, these experiments do not allow to identify a single brain area where dopamine receptors mediating the climbing behavior are located although they suggest that the receptors involved receive a dopaminergic input originating from the substantia nigra.This publication has 33 references indexed in Scilit:
- The effects of strain differences and emotional status of rats on the behavioural and neurochemical effects of chronic treatment with apomorphineProgress in Neuro-Psychopharmacology, 1980
- Ontogenesis of rearing and stereotypy responses to apomorphine in the rat.Journal of Pharmacobio-Dynamics, 1980
- Hypersensitivity of the climbing behaviour response to apomorphine induced by a short depression of dopaminergic neurone activityNeuropharmacology, 1979
- Changes in dopamine receptors in mouse striatum following morphine treatmentsLife Sciences, 1979
- Increased in vivo binding of 3H-Pimozide in mouse striatum following repeated administration of haloperidolLife Sciences, 1978
- Central Catecholamine Neuron Systems: Anatomy and Physiology of the Dopamine SystemsAnnual Review of Neuroscience, 1978
- A gradual score to evaluate the climbing behaviour elicited by apomorphine in micePsychopharmacology, 1978
- Rapid development of hypersensitivity of striatal dopamine receptors induced by alpha-methylparatyrosine and its prevention by protein synthesis inhibitorsLife Sciences, 1977
- Tolerance to hypokinesia elicited by dopamine agonists in mice: Hyposensitization of autoreceptors?Life Sciences, 1977
- 4'-Fluoro-4-(1,4,5,6-tetrahydroazepino[4,5-b]indol-3(2H)-yl)butyrophenonesJournal of Medicinal Chemistry, 1970